Regeneron Pharmaceuticals, Inc. (REGN), is a biotechnology company based in Tarrytown, New York, with a market capitalization of around $82.6 billion. The company specializes in discovering, developing, manufacturing and commercializing transformative medicines for a wide range of serious diseases, including eye diseases, allergies and inflammation, cancer, cardiovascular, neurological, infectious, hematological and rare diseases.
Companies with a market capitalization of $10 billion or more are typically classified as “large cap” stocks, and Regeneron Pharmaceuticals sits comfortably within this group. The biotechnology leader is widely recognized for its diverse portfolio of innovative medicines and its development of innovative therapies.
Shares of the healthcare company have fallen just 4.8% from their 52-week high of $821.11 hit on Jan. 9. Additionally, over the past three months, REGN declined marginally, compared to the 2.4% decline in the broader Nasdaq Composite ($NASX).
Over the past 52 weeks, REGN has gained 11.2%, underperforming the NASX’s 22.2% return over the same time period. However, so far this year, the stock is up 1.3%, outpacing the NASX’s 2.5% decline.
The stock has largely traded above the 50-day moving average since mid-July 2025, but with some fluctuations. The stock is also trading above the 200-day moving average since late October.
Regeneron Pharmaceuticals shares have risen largely due to positive regulatory and pipeline developments and strong investor sentiment. The company reached new highs as optimism grew around FDA approvals and expanded labeling opportunities for key products such as Eylea HD and continued strong sales growth for Dupixent and Libtayo.
However, REGN underperformed its rival, Amgen Inc. (AMGN), which gained 26.9% over the past 52 weeks and 18.6% so far this year.
However, analysts remain very optimistic about its prospects. The stock has a “Strong Buy” consensus rating from the 27 analysts covering it, and the average price target of $870.35 suggests a premium of 11.3% to its current levels.
On the date of publication, Subhasree Kar had no positions (either directly or indirectly) in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. This article was originally published on Barchart.com